Randomized clinical trial of lovastatin in HIV-infected, HAART naïve patients (NCT00721305)

Journal of Infection

Volumn 65, Issue 6, 2012, Pages 549-558

  Montoya, Carlos J ^a   Higuita, Edwin A ^a   Estrada, Santiago ^b   Gutierrez, Francisco J ^a   Amariles, Pedro ^a   Giraldo, Newar A ^c   Jimenez, Margarita M ^d   Velasquez, Claudia P ^e   Leon, Alba L ^a   Rugeles, Maria T ^a   Jaimes, Fabian A ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b Clinical Laboratory Congregacion Mariana   (Colombia)

^c Humax Pharmaceutical   (Colombia)

^d Laproff Laboratories   (Colombia)

^e EPS SURA   (Colombia)

Author keywords

Anti HIV agents; HIV infection; Lovastatin; Randomized controlled trial; Statin

Indexed keywords

CD38 ANTIGEN; HLA DR ANTIGEN; MEVINOLIN; PLACEBO; VIRUS RNA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IMMUNOREACTIVITY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTICHOLESTEREMIC AGENTS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; LOVASTATIN; MALE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84869094102     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.10.016     Document Type: Article

References (41)

1. Douek D.C., Roederer M., Koup R.A. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009, 60:471-484.
2. d'Ettorre G., Paiardini M., Ceccarelli G., Silvestri G., Vullo V. HIV-associated immune activation: from bench to bedside. AIDS Res Hum Retrovir 2011 Apr, 27(4):355-364.
3. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008 Jul 26, 372(9635):293-299. The Antiretroviral Therapy Cohort Collaboration.
4. Calza L., Manfredi R., Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003, 17(6):851-859.
5. Zeiser R., Maas K., Youssef S., Durr C., Steinman L., Negrin R.S. Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology 2009 May, 127(1):18-25.
6. Fehr T., Kahlert C., Fierz W., Joller-Jemelka H.I., Riesen W.F., Rickli H., et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004, 175:83-90.
7. Maziere J.C., Landureau J.C., Giral P., Auclair M., Fall L., Lachgar A., et al. Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium. Biomed Pharmacother 1994, 48(2):63-67.
8. Campbell S.M., Crowe S.M., Mak J. Virion associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS 2002, 16:2253-2261.
9. Liao Z., Cimakasky L.M., Hampton R., Nguyen D.H., Hildreth J.E. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res 2001, 17:1009-1019.
10. Amet T., Nonaka M., Dewan M.Z., Saitoh Y., Qi X., Ichinose S., et al. Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect 2008 Apr, 10(5):471-480.
11. Giguere J.F., Tremblay M.J. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004, 78(21):12062-12065.
12. Nabatov A.A., Pollakis G., Linnemann T., Paxton W.A., de Baar M.P. Statins disrupt CCR5 and RANTES expression levels in CD4+ T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PLoS One May 2007, (5):e470.
13. Namazi M.R. The potential utility of statin vaginal gels in the prevention of HIV transmission. J Drugs Dermatol 2005, 4(1):16.
14. Sklar P.A., Masur H., Grubb J.R., Voell J., Witek J., Ono A., et al. Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. AIDS 2005, 19(10):1109-1111.
15. Carr A. Statins as anti-inflammatory therapy in HIV disease?. J Infect Dis 2011 Mar 15, 203(6):751-752.
16. Narayan S., Hawley N., Giguere P., Badley A.D. Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. HIV Clin Trials 2003, 4(3):164-169.
17. Waters L., Stebbing J., Jones R., Mandalia S., Bower M., Stefanovic M., et al. The effect of statins on HIV rebound and blips. J Acquir Immune Defic Syndr 2005, 39(5):637-638.
18. Manfredi R., Calza L., Chiodo F. Long-term statin use does not act on the temporal trend of CD4 cell count in patients on virologically effective HAART. AIDS 2006, 20(3):455-457.
19. Rodriguez B., Valdez H., Mijch A., Watson K., Lederman M.M., McComsey G.A., et al. Statins blunt HAART-induced CD4 T-cell gains but have no long-term effect on virologic response to HAART. J Int Assoc Physicians AIDS Care (Chic) 2007 Sep, 6(3):198-202.
20. del Real G., Jimenez-Baranda S., Mira E., Lacalle R.A., Lucas P., Gomez-Mouton C., et al. Statins inhibit HIV-1 infection by down-regulating rho activity. J Exp Med 2004 Aug 16, 200(4):541-547.
21. Moncunill G., Negredo E., Bosch L., Vilarrasa J., Witvrouw M., Llano A., et al. Evaluation of the anti-HIV activity of statins. AIDS 2005, 19(15):1697-1700.
22. Probasco J.C., Spudich S.S., Critchfield J., Lee E., Lollo N., Deeks S.G., et al. Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study. Neurology 2008 Aug 12, 71(7):521-524.
23. Negredo E., Clotet B., Puig J., Perez-Alvarez N., Ruiz L., Romeu J., et al. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. AIDS 2006 Feb 28, 20(4):619-621.
24. Ganesan A., Crum-Cianflone N., Higgins J., Qin J., Rehm C., Metcalf J., et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011 Mar 15, 203(6):756-764.
25. Montoya C.J., Jaimes F., Higuita E.A., Convers-Paez S., Estrada S., Gutierrez F., et al. Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial. Trials 2009, 10:41.
26. Prado J.C., Kupek E., Mion D. Validity of four indirect methods to measure adherence in primary care hypertensives. J Hum Hypertens 2007 Jul, 21(7):579-584.
27. Liang K.Y., Zeger S.L. Regression analysis for correlated data. Annu Rev Public Health 1993, 14:43-68.
28. Zeger S.L., Liang K.Y. An overview of methods for the analysis of longitudinal data. Stat Med 1992, 11:1825-1839.
29. DiClemente R.J., Wingood G.M., Harrington K.F., Lang D.L., Davies S.L., Hook E.W., et al. Efficacy of an HIV prevention intervention for African American adolescent girls: a randomized controlled trial. JAMA July 14 2004, 292(2):171-179.
30. Tardif M.R., Gilbert C., Thibault S., Fortin J.F., Tremblay M.J. LFA-1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T-20. Antimicrob Agents Chemother 2009 Nov, 53(11):4656-4666.
31. Waheed A.A., Freed E.O. The role of lipids in retrovirus replication. Viruses 2010 May 1, 2(5):1146-1180.
32. Gilbert C., Bergeron M., Methot S., Giguere J.F., Tremblay M.J. Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol 2005, 18(3):474-489.
33. Melzi S., Carenzi L., Cossu M.V., Passerini S., Capetti A., Rizzardini G. Lipid metabolism and cardiovascular risk in HIV-1 infection and HAART: present and future problems. Cholesterol 2010, 2010:271504.
34. Liu Z., Cumberland W.G., Hultin L.E., Prince H.E., Detels R., Giorgi J.V. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997 Oct 1, 16(2):83-92.
35. Gao F., Linhartova L., Johnston A.M., Thickett D.R. Statins and sepsis. Br J Anaesth 2008 Mar, 100(3):288-298.
36. Rizzardi G.P., Harari A., Capiluppi B., Tambussi G., Ellefsen K., Ciuffreda D., et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002 Mar, 109(5):681-688.
37. Andrieu J.M., Lu W. Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med 2004 May 5, 2:17.
38. Montaner J.S., Zala C., Conway B., Raboud J., Patenaude P., Rae S., et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997 Apr, 175(4):801-806.
39. Moore R.D., Bartlett J.G., Gallant J.E. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One 2011, 6(7):e21843.
40. Paton N.I., Goodall R.L., Dunn D.T., Franzen S., Collaco-Moraes Y., Gazzard B.G., et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012 Jul 25, 308(4):353-361.
41. Jang S.B., Lee Y.J., Lim L.A., Park K.M., Kwon B.J., Woo J.S., et al. Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. Clin Ther 2010 Jan, 32(1):206-216.